Rethinking treatment paradigms for the deployment of SARS-CoV-2 antiviral drugs on the shifting landscape of new variants

by Hentzien M, Owen A, Strub-Wourgaft N, Pèrez Casas CP, Trøseid M, Calmy A. Frontiers in Microbiology 2022. doi: 10.3389/fmicb.2022.998287

Summary: The authors of this opinion piece highlight possible strategies to optimize and protect current and future therapeutic options to treat the most vulnerable patients infected with SARS-CoV-2. They call for combination therapies to be tested in adequately powered clinical trials in immunocompromised patients, both in wealthy and in low-income countries, where HIV-driven immunosuppression is prevalent. If higher efficacy is confirmed, the diversity of possible combinations will enable the tailoring of therapeutic options to individual patient needs and the specific regional context.

Please note that this article is provisionally accepted and the final version will be published soon.

The post Rethinking treatment paradigms for the deployment of SARS-CoV-2 antiviral drugs on the shifting landscape of new variants first appeared on DNDi.